With Alzheimer's disease research progressing, Austin-based Cassava Sciences preps for key trial results
bizjournals.com
business
2022-10-19 20:48:00

Pharmaceutical development is a feast or famine enterprise.

Companies can toil for years without revenue, only to see their values skyrocket when a promising drug candidate shows signs of efficacy.

Even modest steps forward can move markets, especially with an ailment as difficult to combat as Alzheimer's disease.

Case in point: Biogen Inc. and Eisai Co. Ltd. made headlines in late September when they announced that their Alzheimer's drug, lecanemab, showed a 27% reduction in cognitive decline for Alzheimer's patients enrolled in an 1,800-patient trial.
